Cargando…
Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968883/ https://www.ncbi.nlm.nih.gov/pubmed/33471949 http://dx.doi.org/10.1002/cac2.12136 |
| _version_ | 1783666134078193664 |
|---|---|
| author | Ju, Wu‐tong Liu, Ying Wang, Li‐zhen Li, Jiang Ren, Guo‐xing Sun, Jian Tu, Wen‐yong Hu, Yong‐jie Ji, Tong Yang, Wen‐jun Li, Jun He, Yue Wang, Yan‐an Zhang, Chen‐ping Zhong, Lai‐ping Zhang, Zhi‐yuan |
| author_facet | Ju, Wu‐tong Liu, Ying Wang, Li‐zhen Li, Jiang Ren, Guo‐xing Sun, Jian Tu, Wen‐yong Hu, Yong‐jie Ji, Tong Yang, Wen‐jun Li, Jun He, Yue Wang, Yan‐an Zhang, Chen‐ping Zhong, Lai‐ping Zhang, Zhi‐yuan |
| author_sort | Ju, Wu‐tong |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7968883 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79688832021-03-19 Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome Ju, Wu‐tong Liu, Ying Wang, Li‐zhen Li, Jiang Ren, Guo‐xing Sun, Jian Tu, Wen‐yong Hu, Yong‐jie Ji, Tong Yang, Wen‐jun Li, Jun He, Yue Wang, Yan‐an Zhang, Chen‐ping Zhong, Lai‐ping Zhang, Zhi‐yuan Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2021-01-20 /pmc/articles/PMC7968883/ /pubmed/33471949 http://dx.doi.org/10.1002/cac2.12136 Text en © 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Ju, Wu‐tong Liu, Ying Wang, Li‐zhen Li, Jiang Ren, Guo‐xing Sun, Jian Tu, Wen‐yong Hu, Yong‐jie Ji, Tong Yang, Wen‐jun Li, Jun He, Yue Wang, Yan‐an Zhang, Chen‐ping Zhong, Lai‐ping Zhang, Zhi‐yuan Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| title | Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| title_full | Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| title_fullStr | Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| title_full_unstemmed | Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| title_short | Phase III trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| title_sort | phase iii trial of docetaxel cisplatin 5‐fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968883/ https://www.ncbi.nlm.nih.gov/pubmed/33471949 http://dx.doi.org/10.1002/cac2.12136 |
| work_keys_str_mv | AT juwutong phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT liuying phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT wanglizhen phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT lijiang phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT renguoxing phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT sunjian phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT tuwenyong phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT huyongjie phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT jitong phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT yangwenjun phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT lijun phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT heyue phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT wangyanan phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT zhangchenping phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT zhonglaiping phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome AT zhangzhiyuan phaseiiitrialofdocetaxelcisplatin5fluorouracilinductionchemotherapyforresectableoralcancersuggestsfavorablepathologicalresponseasasurrogateendpointforgoodtherapeuticoutcome |